Archaeosomes made of Halorubrum tebenquichense total polar lipids: a new source of adjuvancy.
BACKGROUND
Archaeosomes (ARC), vesicles prepared from total polar lipids (TPL) extracted from selected genera and species from the Archaea domain, elicit both antibody and cell-mediated immunity to the entrapped antigen, as well as efficient cross priming of exogenous antigens, evoking a profound memory response. Screening for unexplored Archaea genus as new sources of adjuvancy, here we report the presence of two new Halorubrum tebenquichense strains isolated from grey crystals (GC) and black mood (BM) strata from a littoral Argentinean Patagonia salt flat. Cytotoxicity, intracellular transit and immune response induced by two subcutaneous (sc) administrations (days 0 and 21) with BSA entrapped in ARC made of TPL either form BM (ARC-BM) and from GC (ARC-GC) at 2% w/w (BSA/lipids), to C3H/HeN mice (25 microg BSA, 1.3 mg of archaeal lipids per mouse) and boosted on day 180 with 25 microg of bare BSA, were determined.


RESULTS
DNA G+C content (59.5 and 61.7% mol BM and GC, respectively), 16S rDNA sequentiation, DNA-DNA hybridization, arbitrarily primed fingerprint assay and biochemical data confirmed that BM and GC isolates were two non-previously described strains of H. tebenquichense. Both multilamellar ARC mean size were 564 +/- 22 nm, with -50 mV zeta-potential, and were not cytotoxic on Vero cells up to 1 mg/ml and up to 0.1 mg/ml of lipids on J-774 macrophages (XTT method). ARC inner aqueous content remained inside the phago-lysosomal system of J-774 cells beyond the first incubation hour at 37 degrees C, as revealed by pyranine loaded in ARC. Upon subcutaneous immunization of C3H/HeN mice, BSA entrapped in ARC-BM or ARC-GC elicited a strong and sustained primary antibody response, as well as improved specific humoral immunity after boosting with the bare antigen. Both IgG1 and IgG2a enhanced antibody titers could be demonstrated in long-term (200 days) recall suggesting induction of a mixed Th1/Th2 response.


CONCLUSIONS
We herein report the finding of new H. tebenquichense non alkaliphilic strains in Argentinean Patagonia together with the adjuvant properties of ARC after sc administration in mice. Our results indicate that archaeosomes prepared with TPL from these two strains could be successfully used as vaccine delivery vehicles.
Gonzalez
Raul O
RO
Programa de Nanomedicinas, Universidad Nacional de Quilmes, Roque Saenz Peña 352, Bernal, Buenos Aires, Argentina. rgonzalez@unq.edu.ar
Higa
Leticia H
LH
Cutrullis
Romina A
RA
Bilen
Marcos
M
Morelli
Irma
I
Roncaglia
Diana I
DI
Corral
Ricardo S
RS
Morilla
Maria Jose
MJ
Petray
Patricia B
PB
Romero
Eder L
EL
D000276:Adjuvants, Immunologic / Q000737:chemistry*; D000818:Animals; D000917:Antibody Formation; D001482:Base Composition; D002522:Chlorocebus aethiops; D019641:DNA, Archaeal / Q000235:genetics; D005260:Female; D055352:Halorubrum / Q000737:chemistry* / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D008055:Lipids / Q000737:chemistry / Q000276:immunology*; D008081:Liposomes / Q000737:chemistry / Q000276:immunology*; D051379:Mice; D008809:Mice, Inbred C3H; D010802:Phylogeny; D012336:RNA, Ribosomal, 16S / Q000235:genetics; D014709:Vero Cells
D000276:Adjuvants, Immunologic; D019641:DNA, Archaeal; D007074:Immunoglobulin G; D008055:Lipids; D008081:Liposomes; D012336:RNA, Ribosomal, 16S
J Liposome Res. 2002 Nov;12(4):353-72
12519630
Syst Appl Microbiol. 1983;4(2):184-92
23194591
Anal Biochem. 1976 May 7;72:248-54
942051
J Immunol. 2000 Nov 1;165(9):5177-85
11046050
Vaccine. 2008 Apr 16;26(17):2043-55
18343538
Int J Toxicol. 2003 Jan-Feb;22(1):9-23
12573945
Ann Microbiol (Paris). 1976 Feb-Mar;127A(2):223-35
786103
Biochim Biophys Acta. 1993 Jul 21;1169(1):46-53
8334149
Vaccine. 2005 May 2;23(24):3210-22
15837222
J Biol Chem. 2001 Jul 20;276(29):27266-71
11373291
Int J Syst Bacteriol. 1997 Jul;47(3):853-7
9226918
Anal Biochem. 1980 May 1;104(1):10-4
6892980
Infect Immun. 2000 Jan;68(1):54-63
10603368
J Mol Biol. 1962 Jul;5:109-18
14470099
Appl Environ Microbiol. 2004 Nov;70(11):6678-85
15528534
Biosci Biotechnol Biochem. 1999 Jun;63(6):969-72
10427681
J Drug Target. 2003;11(8-10):515-24
15203920
Vaccine. 2004 Jun 2;22(17-18):2154-62
15149772
Infect Immun. 2003 Feb;71(2):591-6
12540534
J Bacteriol. 1955 Oct;70(4):484-5
13263323
Int J Syst Evol Microbiol. 2002 Jan;52(Pt 1):149-155
11837297
Int J Syst Bacteriol. 1997 Jan;47(1):73-7
8995805
Int J Syst Evol Microbiol. 2004 Jul;54(Pt 4):1213-1216
15280294
Glycobiology. 2008 Jul;18(7):559-65
18450974
Experientia. 1993 Dec 15;49(12):1027-36
8270029
Chem Phys Lipids. 2003 Dec;126(2):225-32
14623456
Anal Biochem. 1977 Aug;81(2):461-6
907108
J Immunol Methods. 1992 Mar 4;147(2):153-65
1548398
Biochemistry. 1990 May 22;29(20):4929-39
2163672
Eur J Biochem. 1970 Jan;12(1):133-42
4984993
Int J Syst Evol Microbiol. 2006 Jul;56(Pt 7):1583-1588
16825633
Biochim Biophys Acta. 1990 May 24;1024(2):352-66
2162207
Infect Immun. 2002 Apr;70(4):1957-64
11895959
Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463-7
271968
J Lipid Res. 2004 Jan;45(1):194-201
13130126
J Immunol. 2001 Feb 1;166(3):1885-93
11160236
Adv Drug Deliv Rev. 2005 Jan 10;57(3):325-31
15560944
Biochim Biophys Acta. 1996 May 23;1294(2):159-67
8645734
Evolution. 1985 Jul;39(4):783-791
28561359
Extremophiles. 1999 Nov;3(4):253-7
10591015
FEMS Microbiol Lett. 1997 Sep 1;154(1):17-22
9297816
Nucleic Acids Res. 1994 Nov 11;22(22):4673-80
7984417
Glycobiology. 2009 Mar;19(3):267-76
19029107
Can J Microbiol. 1976 Apr;22(4):587-91
1260548
Nucleic Acids Res. 1997 Dec 15;25(24):4876-82
9396791
Adv Drug Deliv Rev. 2002 Oct 4;54(6):863-70
12363435
Carbohydr Res. 2008 Sep 22;343(14):2349-60
18667197